XTRA:BAYNPharmaceuticals
Bayer Stroke Data And Vanderbilt Pact Shape Cardiovascular Pipeline Outlook
Bayer plans to present positive Phase III results from its OCEANIC-STROKE trial of asundexian at an upcoming international stroke conference.
The company has also announced a new multi year R&D partnership with Vanderbilt University Medical Center focused on cardiovascular and kidney diseases.
Bayer, traded as XTRA:BAYN, currently has a share price of €44.56, with the stock up 17.3% over the past month and 106.9% over the past year. These new clinical and research developments arrive as the...